A Phase I/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects with Non-small Cell Lung Caleer (NSCL)
Brief description of study
If you have been diagnosed with Non-small Cell Lung Cancer (NSCLC), you may qualify for this Phase 1/2 study. The main goal of this study is to determine the safety of the investigational combination of drugs durvalumab and tremelimuab (either one or both) with an investigational vaccine and to examine the impact these drugs have on your cancer.
Clinical Study Identifier: s16-01612
ClinicalTrials.gov Identifier: NCTs16-01612
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
